Similarly, Rooney et al. confirmed that RUNX1 acts as an oncogenic driver in ccRCC, associating elevated RUNX1 expression with significantly poorer clinical outcomes compared to lower expression levels [103]. The gene discussed is RUNX1; the disease is nonpapillary renal cell carcinoma.